About Us

Interstitial NanoSystems is the specialist vehicle launched from the bionanotechnology activities within Nanotechnology Victoria.

Interstitial NS consists of a dynamic and experienced team who are committed to the commercial development of new, world leading drug delivery technologies. Behind Interstitial NS is a portfolio of several patents, licenses and assets valued at over $10 million.

Interstitial NS Team

Dr Bob Irving - Chief Executive Officer Scientific and Commercial Director, and Director for Delivery and Sensing with Nanotechnology Victoria Ltd for over four years, Bob has been responsible for developing the BioNano portfolio. Bob managed the Protein Diagnostics Program of CRC for Diagnostics for four years and was responsible for the development and commercialisation of the molecular evolution technologies into EvoGenix Pty Ltd. Bob also developed technologies leading to the start-up company Avipep and managed  projects in biotechnology companies in Canada for 6 years. Bob’s PhD was awarded for his work at the Imperial Cancer Research Fund, London, on prostate cancer.

Dr Michelle Critchley - Director, Operations and Development Previously with CSIRO and appointed in 2004 to work on NanoVic bionanotechnology related projects. Michelle managed the NanoVic transdermal delivery project and has experience in a variety of client industries in biotechnology, aerospace, food safety, Legionella control and biosensor development. Michelle is responsible for managing the Interstitial NS intellectual property portfolio.